Key Highlights
- Evolent Health (NYSE:EVH) was trading down 5.47% at USD 3.71 in intraday market data on Thursday, November 19, 2026, leaving the low-priced stock well under USD 5.
- Third-quarter Revenue was USD 725.4 million against USD 479.5 million a year earlier, yet adjusted EBITDA fell to USD 34.3 million from USD 39.0 million.
- The medical expense ratio rose to 93.0% from 85.0%, and adjusted EBITDA Margin narrowed to 4.7% from 8.1% in the quarter.
- Full-year 2026 adjusted EBITDA guidance was raised to USD 130.0 million to USD 135.0 million, while revenue guidance of USD 2.6 billion to USD 2.7 billion was reiterated.
Slide Arrives With No New Company Announcement
Evolent Health (NYSE:EVH) was trading down 5.47% at USD 3.71 in intraday market data on Thursday, November 19, 2026. No company announcement explaining the move was found in searches covering November 17 to November 19, 2026, and the most recent verified event is the third-quarter release of November 5, 2026. Evolent is a Washington, D.C.-based provider of specialty care management services, including cancer and cardiology programs, sold to health plans and provider groups. A fall of this size on a stock priced under USD 5 is not by itself news, so the drop is best read against the fundamentals below rather than as a response to a specific headline. The shares have not been tied to any analyst action or filing in the verified window, and published reaction pieces about earlier Evolent selloffs date from 2025 and are not used here.
Revenue Surge Meets a Higher Medical Expense Ratio
For the quarter ended September 30, 2026, Evolent reported revenue of USD 725.4 million versus USD 479.5 million, and a net loss attributable to common shareholders of USD 23.6 million, or USD 0.21 a share, compared with USD 26.9 million, or USD 0.24. Adjusted income attributable to common shareholders was USD 7.3 million, or USD 0.06 a share. The medical expense ratio, the share of revenue paid out as medical costs under risk-based contracts, climbed to 93.0% from 85.0%, which compressed adjusted EBITDA to 4.7% of revenue. Nine-month revenue was USD 1,874.1 million and the nine-month net loss was USD 78.6 million. Nine-month revenue of USD 1,874.1 million is about 72% of the USD 2.6 billion lower end of full-year guidance, which implies a fourth quarter of at least about USD 726 million (both calculated).
Debt Load and Contract Wins Frame the Risk
At September 30, 2026, cash and equivalents were USD 148.3 million against net long-term Debt of USD 969.5 million, which implies about USD 821.2 million of debt net of cash (calculated). The company said it intends to apply up to USD 50 million to reduce indebtedness by year-end. It renewed its largest Surgical Management contract for four years, expanded oncology services for an existing client covering about 1 million commercial lives from January 1, 2027, and extended a national payer relationship into 11 more states. Margin pressure, Leverage and medical cost trends remain the main risks. Evolent also reported seven renewals and new revenue agreements so far this year, though contract wins take time to convert into margin.
Where Things Stand
Evolent Health (NYSE:EVH) is down 5.47% without a company announcement that explains it, so the move should not be attributed to any single event. The latest verified picture is mixed: revenue rose sharply and guidance for adjusted EBITDA was raised, but the medical expense ratio reached 93.0% and debt remains large relative to cash. Next markers are the planned debt reduction by year-end, the January 1, 2027 oncology go-live and the fourth-quarter report. The company has not commented on today's trading.




_11_19_2026_18_15_38_890267.jpg)

Please wait processing your request...